Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Omalizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 974,765Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 20Xolair

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2019 Revenue in Millions : 2,028

    2018 Revenue in Millions : 1,969

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2020 Revenue in Millions : 1,251

    2019 Revenue in Millions : 1,173

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 2,121

    2019 Revenue in Millions : 2,194

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2021 Revenue in Millions : 1,428

    2020 Revenue in Millions : 1,251

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 2,090

    2020 Revenue in Millions : 2,018

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 1,365

    2021 Revenue in Millions : 1,428

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 2,414

    2021 Revenue in Millions : 2,090

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 2,525

    2022 Revenue in Millions : 2,414

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 1,463

    2022 Revenue in Millions : 1,365

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Xolair

    Omalizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Antibody Engineering
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2014 Revenue in Millions : 26.80%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF